Summary
This study investigates how ginger-derived exosome-like nanoparticles (GELNs) interact with specific gut bacterial families to reshape the metabolic environment in the context of cancer immunotherapy. Using a humanised gnotobiotic mouse model, the authors demonstrate that GELN-derived miRNA aly-miR159a-3p suppresses bacterial phospholipase C expression, leading to increased DHA accumulation, which in turn enhances the efficacy of anti-PD-L1 checkpoint inhibitor therapy in melanoma. The findings suggest a mechanistic pathway through which dietary plant-derived nanoparticles may potentiate immunotherapy responses via microbiota-mediated metabolite modulation.
UK applicability
This preclinical study was conducted in a gnotobiotic mouse model and is not specific to any national context; however, its findings are relevant to UK oncology, nutrition science, and microbiome research communities, particularly as interest grows in dietary interventions to support cancer immunotherapy outcomes in NHS and clinical trial settings.
Key measures
Gut microbiota composition (Lachnospiraceae, Lactobacillaceae); DHA accumulation levels; bacterial phospholipase C (PLC) expression; anti-PD-L1 therapy efficacy in melanoma; uptake of DGDG and glycine by bacterial families; miRNA (aly-miR159a-3p) activity
Outcomes reported
The study measured the effects of ginger-derived exosome-like nanoparticles on gut microbiota composition and metabolite profiles, specifically docosahexaenoic acid (DHA) accumulation, and assessed their impact on anti-PD-L1 immunotherapy efficacy in a humanised gnotobiotic mouse model of melanoma.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.